Our scientific approach

RADAR-AD (Remote Assessment of Disease and Relapse – Alzheimer’s Disease) aims to identify biosignatures indicative of functional decline in early Alzheimer’s Disease (AD) by using remote monitoring techniques. The goal is to do so by exploring how mobile technologies – such as smart phones, wearables and home-based sensors – can measure disability progression associated with AD with greater sensitivity than currently used methods, such as direct observation or caregiver recall. 

To reach our goal, we will assess which functional domains are most relevant for people with early AD and can most accurately predict disease progression. This will be done via statistical analysis of available longitudinal cohorts, patient focus groups, and literature reviews. The outcome of this assessment will be used to identify devices that are well-suited to accurately measure these relevant functional domains. These measurements can include physiological state, behavioural and cognitive biomarkers, as well as active or passive assessments. Device selection will also be based on functionality, patient acceptability and value for money. In addition to standard devices (like smartphones or fitness trackers), we will also explore novel and complex devices. The combination of using standard devices and novel, complex devices allows for feasible and low-risk data collection, as well as the maintenance of a highly innovative approach.

The devices will be assessed in an exploratory study for their utility in making group comparisons, associations with other cognitive, functional, and biomarker measures, and modelling functional decline. 

Data will be captured and modelled by using the RADAR-base platform, which is a generic data management and modelling infrastructure. RADAR-base was initially developed for the RADAR-CNS project and is designed in a flexible way so that it can easily be adapted to accommodate other satellite projects that revolve around remote measurement technologies. 

To pave the way for such potentially ground-breaking technologies and approaches, it is critical to proactively identify and address potential barriers to effective implementation. We are therefore working closely together with patients, caregivers and regulators to ensure that adequate regulatory frameworks are developed, that technologies are safe and convenient to use, and that the data and privacy of patients are protected.

Our research